What is Axoft?
Axoft is pioneering a transformative approach to healthcare by developing bioinspired, scalable implants designed to establish long-term communication with the nervous system. This innovative technology aims to revolutionize clinical outcomes, enhance individual health, and redefine the human experience. The company's focus on creating seamless, enduring interfaces with the body positions it at the forefront of medical device innovation, addressing critical needs in patient care and rehabilitation.
How much funding has Axoft raised?
Axoft has raised a total of $63M across 2 funding rounds:
Angel/Seed
$8M
Series A
$55M
Angel/Seed (2022): $8M with participation from The Engine, Amino Capital, Alumni Ventures, and Decent Capital
Series A (2026): $55M led by Charoen Pokphand Group, Hillhouse, Alumni Ventures, and Gaorong Capital
Key Investors in Axoft
The Engine
The Engine, built by MIT, is a venture firm investing in the next generation of Tough Tech, focusing on solutions for human health, climate change, and advanced systems. They support transformative technologies aimed at creating a more sustainable and resilient world.
Amino Capital
Amino Capital is a global venture capital firm specializing in investments that leverage data moats and network effects, backing companies across Consumer, PLG SaaS, Frontier Tech, AI, and Web3 from seed to growth stages.
Charoen Pokphand Group
Charoen Pokphand Group (CP Group) is a Thai multinational conglomerate with significant interests in food production and telecommunications, committed to promoting sustainable development and responsible business practices.
What's next for Axoft?
With the recent infusion of $55M in a major strategic investment, Axoft is poised for significant expansion. This capital injection, following a substantial prior funding round, indicates a strong investor confidence in the company's technology and its potential to scale. The enterprise-level funding suggests Axoft is moving beyond early-stage development into a phase of robust growth, likely focusing on clinical trials, regulatory approvals, manufacturing scale-up, and market penetration. The strategic nature of the recent financing may also point towards partnerships or collaborations aimed at accelerating market adoption and impact.
See full Axoft company page
